Thursday, September 308:30 – 9:00 – Welcome, Chairman’s Remarks, and Introductions
Karen Avery
Director of Foundation Relations, Smithsonian Institution
Steve Case
Chairman, Accelerate Brain Cancer Cure
Max Wallace
CEO, Accelerate Brain Cancer Cure
9:00 – 9:30 – Clinical Treatment of GBM – Where Are We and Where Do We Need to Go?
Mike Prados
Director of Translational Research in Neuro-Oncology, UCSF
9:45 – 12:00 – Molecular Elucidation of Brain Cancer
Lynda Chin
Professor of Dermatology, Harvard Medical School
Stephen Friend
President, Co-Founder and Director, Sage BioNetworks
Markus Bredel
Director, Radiation Oncology Brain Tumor Laboratory, UAB
1:00– 2:45 – New Strategies and Opportunities in Targeting GBM
Paul Mischel
Professor of Pathology, UCLA
Heidi Phillips
Senior Scientist, Genentech
David Schenkein
CEO, Agios Pharmaceuticals
3:00 – 4:15
Martin Brown
Director, Division of Radiation and Cancer Biology, Stanford
Graeme Bilbe
Global Head of Neuroscience Research, Novartis
Friday, October 18:30 – 9:00 – Integration of Clinical Genomics into the Discovery and Development of Novel Cancer Therapies
Neil Gibson
Vice President and Chief Scientific Officer, Pfizer Oncology
9:00 – 11:00 – New Initiatives in Preclinical Animal Models for GBM
Terry Van Dyke
Chief, Mouse Cancer Genetics Program, NCI
David James
Professor of Neurological Surgery, UCSF
Neal Goodwin
The Jackson Laboratories
11:00 – 11:30 – New Clinical Trials in Brain Cancer
Karen Aboody
Associate Professor, Neurosciences, City of Hope
11:30 – 11:45 – Closing Remarks
Max Wallace
CEO, Accelerate Brain Cancer Cure